x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243186
| Product Information | |
|---|---|
| CAS No. | 869974-19-6 |
| Formula | C28H25N3O4 |
| Molecular Weight | 467.52 |
| SMILES | O=C(C1=NC=C(C2=CC=C(C3(C(N4C[C@]5(CC4)OC(C6=C5C=CC=C6)=O)=O)CC3)C=C2)C=C1)NC |
| Target | Glucocorticoid Receptor, Mineralocorticoid Receptor, 11β-HSD |
| Product Description | INCB13739 is an orally active, potent, selective and tissue-specific11β-HSD1 (11β-hydroxysteroid dehydrogenase 1) inhibitor, with IC50 values of 3.2 nM (11β-HSD1 enzymatic) and 1.1 nM (11β-HSD1 PBMC), respectively. INCB13739 can be used for type 2 diabetes mellitus (T2DM) and obesity research. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Color | Off-white to light yellow |
| Purity | 99.79% |
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | Powder: -20°C, 3 years In solvent: -80°C, 6 months; -20°C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
